Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
49 results about "Clinical method" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The clinical method is the means by which physicians discover facts about the sick or well patient and enter them into the diagnostic and therapeutic process in equal partnership with information about disease, pathophysiology, and technology. The inadequacy of the clinical method as currently taught and practiced creates problems...
Apparatus and method for chronically monitoring heart sounds for deriving estimated blood pressure
ActiveUS6869404B2Simplified and minimized in sizeElectrocardiographyAuscultation instrumentsRegression analysisT wave
A minimally invasive, implantable heart sound and ECG monitor and associated method for deriving blood pressure from heart sound data. The device is equipped with an acoustical sensor for detecting first and second heart sounds which are sampled and stored during sensing windows following R-wave and T-wave detections, respectively. ECG and heart sound data are stored in a continuous, looping memory, and segments of data are stored in long-term memory upon an automatic or manual data storage triggering event. Estimated blood pressure is calculated based on custom spectral analysis and processing of the first and second heart sounds. A calibration method includes measuring a patient's blood pressure using a standard clinical method and performing regression analysis on multiple spectral variables to identify a set of best fit weighted equations for predicting blood pressure. Concurrent ECG and estimated blood pressure may be displayed for review by a physician.
Owner:MEDTRONIC INC
Medical Device, Method And System For Temporary Occlusion Of An Opening In A Lumen Of A Body
InactiveUS20110172697A1Avoid communicationAvoid flowStentsBalloon catheterTemporary occlusionVideo fluoroscopy
A medical system is disclosed that has three basic components; a retractable sheet, a first balloon that has a centrally arranged hollow, and a collapsible / expandable support structure at the hollow. The first balloon is for instance mounted / molded onto the exterior surface of the support structure. The aggregate of support structure and the first balloon is positioned, and once the sheet has been retracted from the first balloon, the first balloon is inflated. The support structure may be self-expandable or expandable by an expansion unit, such as a further balloon arranged at its inside. The lumen of the support structure is chosen to be smaller than that of a main lumen. The outside diameter of the inflated first balloon is chosen to be larger than the interior diameter of the main lumen. This procedure may be done using standard Seldinger technique and fluoroscopy. This makes the system user friendly and increases patient safety, as a well established clinical method may be used with some modifications according to the invention.
Owner:AEEG
Clinical method and system for patient to acquire right to know medical treatment
InactiveCN102004862AShorten the timeUnderstand and monitor the diagnosis and treatment processSpecial data processing applicationsDatabase serverComputer terminal
The invention relates to a clinical method and a clinical system for a patient to acquire right to know medical treatment, and belongs to the technical field of information. The system comprises a patient terminal, a platform server, a hospital information system (HIS) interface server, a database server, a doctor work station and a network, and is characterized in that: the patient terminal, the platform server, the HIS interface server, the database server and the doctor work station are connected with one another through the network; and the HIS interface server is connected with an HIS through the network and acquires diagnosis and treatment data. The patient logs in the platform server through the patient terminal, and the platform server verifies the identity of the patient, acquires data from the database server and the HIS interface server and sends the data to the patient terminal. Multiple kinds of related information is provided for the patient, the problem of unequal doctor and patient information is solved, the patient acquires the right to know the medical treatment, and doctor and patient conflicts are furthest reduced.
Owner:王兴强
Transcatheter tumor immunoembolization
InactiveUS20070269406A1Providing therapyPrevent implantationSpecial deliveryPeptide/protein ingredientsAbnormal tissue growthIMMUNE STIMULANTS
Methods of inducing a cancer-specific immune response are disclosed through administration of an immune stimulant in the context of tumor cell death induction. Currently used clinical methods of inducing localized tumor cell death are modified to optimize immune response induction. One embodiment of the invention discloses pharmaceutical compositions and kits for modifying the palliative procedure of transarterial chemoembolization so as to promote uptake and presentation of tumor antigens in an immunostimulatory microenvironment, thereby allowing for induction of T cell, B cell and NK responses, which control not only local, but also systemic tumor growth and metastasis.
Owner:ICHIM THOMAS E
Inhibitors of human plasmin derived from the kunitz domains
InactiveUS6953674B2Peptide/protein ingredientsMammal material medical ingredientsPlasminADAMTS Proteins
The invention features novel polypeptides homologous to the first Kunitz domain (K1) of lipoprotein associated coagulation inhibitor (LACI) that are capable of inhibiting plasmin, and nucleic acids encoding these proteins. The invention also features the use of such polypeptides in diagnostic, therapeutic and clinical methods.
Owner:DYAX CORP
Minimally invasive clinical treatment method for closure of umbilical hernias
The present invention is a minimally invasive clinical method for closing hernias and other abnormal openings existing within the body; and is a unique alternative to conventional surgery and routine surgical techniques for correcting such medical defects. The clinical applications for the present methodology can be used for the in-vivo closure of small sized lumens and voids which naturally occur and exist internally within the soft connective tissue and organs of the living human body; can be employed to advantage for the closure of hernias generally; and is focused upon the closure of umbilical hernias specifically.
Owner:CHILDRENS MEDICAL CENT CORP
Clinical method for the genetic screening of newborns using tandem mass spectrometry and internal standards therefor
InactiveUS20060008922A1Simple methodRapid sample throughputParticle separator tubesDisease diagnosisMetaboliteTandem mass spectrometry
A method for screening newborns using electrospray tandem mass spectrometry. The method improves the current protocols that use tandem mass spectrometry by assuring accurate and consistent results at the clinical level through enhanced quality controls and quality assurance protocols as applied to the scan profiling and sample preparation of blood spots from newborns. Specific additives are used in precise concentrations of internal standards, employing detailed controls adapted to distinguish twenty metabolites, which are scanned and vigorously compared to known spectra results. Revealing peaks, metabolite concentration, and scan intensities in the quality assurance steps are then compared to a range of thresholds to determine whether or not the sample is contaminated, drug-ridden, diagnosable, or unacceptable. All spectra results and quality assurance flags are organized in spreadsheet form and exported to a database where values are compiled and stored for daily output results and trend analysis. The method provides for high-throughput and quality results, having a consistent predictability for genetically testing newborns efficiently and accurately.
Owner:PERKINELMER GENETICS
Method of assessing risk of multiple births in infertility treatments
ActiveUS20120016184A1Reduce chanceReduce the prevalenceMedical simulationAnimal reproductionObstetricsEmbryo
Provided is a multiple birth prognostic tool that is used to analyze data in order to predict a multiple birth event in a female human patient undergoing an infertility treatment. The MBP prognostic tool may also be used to enhance the accuracy of diagnostic or prognostic tests that predict embryo viability. The MBP prognostic tool of the present invention may be clinic specific or it may be modified to be used in a multi-clinic approach.
Owner:UNIVFY
Clinical method for the genetic screening of newborns using tandem mass spectrometry
InactiveUS20060014297A1Simple methodRapid sample throughputParticle separator tubesDisease diagnosisMetaboliteTandem mass spectrometry
A method for screening newborns using electrospray tandem mass spectrometry. The method improves the current protocols that use tandem mass spectrometry by assuring accurate and consistent results at the clinical level through enhanced quality controls and quality assurance protocols as applied to the scan profiling and sample preparation of blood spots from newborns. Specific additives are used in precise concentrations of internal standards, employing detailed controls adapted to distinguish twenty metabolites, which are scanned and vigorously compared to known spectra results. Revealing peaks, metabolite concentration, and scan intensities in the quality assurance steps are then compared to a range of thresholds to determine whether or not the sample is contaminated, drug-ridden, diagnosable, or unacceptable. All spectra results and quality assurance flags are organized in spreadsheet form and exported to a database where values are compiled and stored for daily output results and trend analysis. The method provides for high-throughput and quality results, having a consistent predictability for genetically testing newborns efficiently and accurately.
Owner:PERKINELMER GENETICS
Detection of high-risk intraductal papillary mucinous neoplasm and pancreatic adenocarcinoma
ActiveUS20130109035A1Disease diagnosisBiological testingAdenocarcinomaIntraductal papillary mucinous neoplasm
Owner:RUTGERS THE STATE UNIV +1
Test strip device with lid-provided pretreatment portion
The invention relates to a test device, which has a pretreatment part covered by a cover (2) having a hole (3) and connected by a hinge (A). The pretreatment part is mounted on the same base (1) as a test strip (not shown). In the lid (2) and the lid of the base are devices (7, 8 and 9) for supporting, fastening and fixing the pretreatment layers, forming excess liquid collection chambers (6), and controlling the flow of sample solutions and diluents. The test device is used in field tests and clinical methods, especially in emergency situations where fast results are required (Fig. 8).
Owner:MEDIX BIOCHEMICA
Methods of monitoring and analyzing metabolic activity profiles diagnostic and therapeutic uses of same
A method of measuring a metabolic activity (MA) of a cell is provided. The method comprising independently measuring in an extracellular environment of the cell, time-dependent acidification profiles due to secretion of:(i) non-volatile soluble metabolic products;(ii) non-volatile soluble metabolic products and volatile soluble metabolic products; and(iii) volatile soluble metabolic products;wherein at least one of the time dependent acidification profiles is indicative of the metabolic activity of the cell. Also provided are clinical methods which make use of the assay.
Owner:RAMOT AT TEL AVIV UNIV LTD
Application of lncRNA combination to preparation of product for predicting renal clear cell carcinoma prognosis and molecular targeted medicine treatment sensitivity
InactiveCN108277283ASensitivity PreciseSensitivity Rapid JudgmentMicrobiological testing/measurementMolecular targeted drugRenal clear cell carcinoma
The invention discloses application of lncRNA combination to preparation of a product for predicting renal clear cell carcinoma prognosis and molecular targeted medicine treatment sensitivity. The lncRNA or the lncRNA combination serving as a detection target point is applied to preparation of the product for predicting renal clear cell carcinoma prognosis and molecular targeted medicine treatmentsensitivity, and the lncRNA or the lncRNA combination is selected from any one or more of SEQ ID NO.1 to SEQ ID NO.4. A new clinical method is provided for evaluating prognosis of patients sufferingfrom renal clear cell carcinoma, new reference advice is provided for auxiliary treatment after operation of the renal clear cell carcinoma, and important clinical significance and popularization andapplication prospect in the aspects of timely taking effective clinical measures, formulating an individualized diagnosis and treatment scheme and finally increasing the survival rate of the patientssuffering from the renal clear cell carcinoma are achieved.
Owner:NANJING GENERAL HOSPITAL NANJING MILLITARY COMMAND P L A
Method of assessing risk of multiple births in infertility treatments
ActiveUS9348972B2Reduce chanceReduce the prevalenceMedical simulationAnimal reproductionObstetricsEmbryo
Provided is a multiple birth prognostic tool that is used to analyze data in order to predict a multiple birth event in a female human patient undergoing an infertility treatment. The MBP prognostic tool may also be used to enhance the accuracy of diagnostic or prognostic tests that predict embryo viability. The MBP prognostic tool of the present invention may be clinic specific or it may be modified to be used in a multi-clinic approach.
Owner:UNIVFY
Pre-clinical method for monitoring serial changes in circulating breast cancer cells in mice
InactiveUS20090117532A1Dead animal preservationMaterial analysisAbnormal tissue growthClinical study
The CellTracks® System provides a system to enumerate CTC's in blood. The system immunomagnetically concentrates epithelial cells, fluorescently labels the cells and identifies and quantifies CTC's. The absolute number of CTC's detected in the peripheral blood tumor load is, in part, a factor in prediction of survival, time to progression, and response to therapy. Pre-clinical studies of circulating tumor cells (CTC's) have been limited by the inability to repetitively monitor CTC's in animal models. The present invention provides a method to enumerate CTC's in blood samples obtained from living mice, using a protocol similar to an in vitro diagnostic system for quantifying CTC's in patients. Accordingly, this technology can be adapted for serial monitoring of CTC's in mouse xenograft tumor models of human breast cancer.
Owner:VERIDEX LCC
Gene Therapy for Skin Disorders Using Needleless Syringes
InactiveUS20070293447A1Avoid painAvoid pain and risk of infectionMetabolism disorderPharmaceutical delivery mechanismDiseaseA-DNA
The present invention provides highly useful clinical methods for treating skin disorders, particularly intractable skin disorders. Specifically, the methods comprise injecting / subcutaneously introducing a 10 μg to 10 mg dose of a polynucleotide, such as a DNA, oligonucleotide, RNA, siRNA, and antisense, around a lesion associated with a skin disorder, such as a wound, cutaneous ulcer, or psoriasis, using a needleless syringe that injects a pharmaceutical liquid by using gas pressure or the elastic force of an elastic member to drive a piston.
Owner:ANGES MG INC
A picometer-diameter pore in an inorganic membrane for sequencing protein
InactiveUS20190064110A1Easy to detectTotal current dropMaterial analysis by electric/magnetic meansBiological testingSputteringCrystallography
Disclosed are thin inorganic membranes having a defined topography that includes pores having a defined diameter of nanometer and sub-nanometer diameter. The thin membranes are resistant to protein denaturing agents, and may be employed in analytical and clinical methods for identifying single amino acid residues within the sequence of a protein, and the pores are other than MspA pores. Methods for making a thin inorganic membrane with nanopore and sub-nanopore topography and conical cone structure are also disclosed. The thin inorganic membrane may be comprised of any denaturant-resistant materials, such as silicon nitride. A method for manufacturing the thin inorganic membrane with nanopores is also provided, and provides a thin surface with a defined conical topography, the nanopores being provided on the membrane surface with an electron beam sputtering technique.
Owner:UNIV OF NOTRE DAME DU LAC
Beta interferon for the treatment of chronic spinal cord injury
InactiveUS7462349B2Novel and effective treatmentReducing progressive secondary damagePeptide/protein ingredientsBeta interferonsClinical method
The invention is intended to adapt an already established clinical procedure for the treatment of multiple sclerosis (MS)—the use of beta interferon—to treat chronic human spinal cord injury. The present invention relates to the prevention of chronic inflammation and demyelination following spinal cord injury.
Owner:KALDERON NURIT
Method of colorectal cancer detection by using radiolabeled anti-GRP78 peptide
The present disclosure describes techniques used for colorectal cancer detection. Position and distribution of colorectal cancer tumor are detected through nuclear imaging. Alternatively, stage of colorectal cancer is identified by shading value in tumor. Thus, the present disclosure provides a safe and noninvasive clinical method for diagnosing and tracing level and distribution of colorectal cancer before and after treatment.
Owner:INST NUCLEAR ENERGY RES ROCAEC
Methods For The Selective Treatment Of Tumors By Calcium-Mediated Induction Of Apoptosis
InactiveUS20110098232A1Exceed capacityImprove leakageCyclic peptide ingredientsAntineoplastic agentsCalcium handlingCalcium influx
Available evidence indicates that tumor cells exhibit consistent abnormalities in Calcium influx and intracellular storage of sequestered Calcium when compared to normal cells. The present invention provides clinical methods by which such differences are exploited to induce Apoptosis selectively in tumor cells while sparing normal cells. These methods are based upon employing drugs that, acting alone or in synergistic combinations, produce an increase in intracellular Calcium loading such that either or both of two major Apoptotic pathways are triggered to produce selective killing of malignant cells. Since the invention is based upon fundamental cell cycle requirements, to the extent that Calcium handling abnormalities are a general characteristic of the malignant state, the methods presented here are widely applicable regardless of tissue of origin and degree of cellular de-differentiation.
Owner:ZEILIG CHARLES E
Methods of monitoring and analyzing metabolic activity profiles diagnostic and therapeutic uses of same
ActiveUS8728758B2Bioreactor/fermenter combinationsBiological substance pretreatmentsExtracellularAssay
Owner:RAMOT AT TEL AVIV UNIV LTD
Minimally invasive clinical treatment method for closure of umbilical hernias
The present invention is a minimally invasive clinical method for closing hernias and other abnormal openings existing within the body; and is a unique alternative to conventional surgery and routine surgical techniques for correcting such medical defects. The clinical applications for the present methodology can be used for the in-vivo closure of small sized lumens and voids which naturally occur and exist internally within the soft connective tissue and organs of the living human body; can be employed to advantage for the closure of hernias generally; and is focused upon the closure of umbilical hernias specifically.
Owner:CHILDRENS MEDICAL CENT CORP
Diagnosis of Metastases in Hnscc Tumours
InactiveUS20090005258A1Nucleotide librariesMicrobiological testing/measurementLymphatic SpreadOncology
The invention relates to the detection or prediction of metastases of head and neck squamous cell carcinoma (HNSCC) with the use of gene expression profiles. A gene signature has been identified which is able to detect or predict the occurrence of these metastases better than current clinical methods. Part of the invention are micro-arrays comprising this signature and methods for performing the detection and / or prediction.
Owner:UMC UTRECHT HLDG BV
Novel and highly-sensitive detection method for latent human cytomegalovirus (HCMV) in cell
InactiveCN103627822AHigh homologyMicrobiological testing/measurementPeripheral blood mononuclear cellHCMV Infection
The invention provides a novel and highly-sensitive detection method for human cytomegalovirus (HCMV). The method represents a nested quantitative PCR (polymerase chain reaction) technique which can detect both free HCMV and HCMV that infects a cell, and is characterized in that nucleic acid is extracted from human peripheral blood mononuclear cells (PBMCs), and a first round of PCR amplification is carried out through specific outer upstream and downstream primers; with the products of the first round of PCR amplification serving as a template, a second round of quantitative PCR amplification is carried out through specific inner upstream and downstream primers. By adopting the detection method provided by the invention, the HCMV detection sensitivity can reach 8 copies per microliter. Compared with the ELISA (enzyme-linked immunoabsorbent assay) method, compared with the ELISA method, the method adopting the PCR method for the detection of the latent HCMV infection has the advantages of rapidness, simplicity, high sensitivity, strong specificity, good stability and the like, and is a clinical method for early detection and diagnosis.
Owner:WENZHOU MEDICAL UNIV
Methods for the selective treatment of tumors by calcium-mediated induction of apoptosis
InactiveUS20070054874A1Exceed capacityImprove leakageBiocideCarbohydrate active ingredientsAbnormal tissue growthApoptosis
Disclosed are clinical methods for inducing apoptosis selectively in tumor cells while sparing normal cells. These methods employ drugs that, acting alone or in synergistic combinations, produce an increase in intracellular Calcium loading such that either or both of two major apoptotic pathways are triggered to produce selective killing of malignant cells. The methods disclosed are widely applicable regardless of tissue of origin and degree of cellular de-differentiation.
Owner:CYCLEGEN
Preparation method of teeth whitening liquid based on atmospheric pressure low-temperature plasma
InactiveCN103359823ANo smellNo stimulationCosmetic preparationsWater/sewage treatment by irradiationElectricityHigh concentration
The invention provides a preparation method of teeth whitening liquid based on atmospheric pressure low-pressure plasma, aiming at overcoming the shortcoming that an existing clinical method of whitening teeth by gel containing high-concentration hydrogen peroxide has low efficiency and irritates the teeth and soft tissues. The preparation method is characterized in that the preparation method depends on physical equipment, namely the low-temperature plasma, a certain amount of gas is introduced into a low-temperature plasma generation device, and the low-temperature plasma generation device is electrically driven; a certain amount of water is taken, and the device is placed above the liquid surface of the water solution (attached drawing 2) or below the liquid surface of the water solution (attached drawing 1) by a certain distance so as to stimulate the interaction between the plasma and the water; and after the plasma and the water interact for a certain time, the water becomes the teeth whitening liquid based on the atmospheric pressure low-pressure plasma. The teeth whitening liquid prepared by the method is non-toxic, non-irritant and free of peculiar smell and residues and has a very strong teeth whitening effect.
Owner:PEKING UNIV
Inhibitors of human plasmin derived from the kunitz domains
InactiveUS20050186649A1Inhibition is effectivePeptide/protein ingredientsTissue culturePlasminLipoprotein-Associated Coagulation Inhibitor
This invention provides: novel proteins, which are homologous to the first Kunitz domain (K1) of lipoprotein-associated coagulation inhibitor (LACI), and which are capable of inhibiting plasmin; uses of such novel proteins in therapeutic, diagnostic, and clinical methods; and polynucleotides that encode such novel proteins.
Owner:DYAX CORP
Deoxycytidine kinase binding compounds
Owner:RGT UNIV OF CALIFORNIA
Tracheal cannula fixing article used after tracheotomy
InactiveCN102430178AReduces the chance of accidental tube disengagementReduce skin problemsTracheal tubesTracheotomyNeck parts
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Clinical method for the immunomodulatory and vaccine adjuvant use of poly-ICLC and other dsRNAs
ActiveUS7834064B2Low toxicityImprove the immunityBiocidePeptide/protein ingredientsMicroorganismAutoimmune disease
An improved understanding and method for the clinical adjuvant and immunomodulatory use of dsRNAs and ply-ICLC in particular, alone or in conjunction with other drugs and various vaccines designed to prevent or treat various microbial, viral, neoplastic, autoimmune diseases, and or degenerative diseases.
Owner:SALAZAR ANDRES MARIO
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com